While Medtronic was making headlines in June as one of its defibrillators was implanted in Vice President Dick Cheney, its corporate treasurer was toiling over the geometry of days sales outstanding (DSOs) while its CFO was nailing down another acquisition.

It was business as usual at the Minneapolis-based maker of medical devices, and that's what has endeared the rapidly growing company to investors.

Medtronic–whose co-founder Earl Bakken invented the first battery-operated pacemaker in 1957–dominated the market for heart-treatment devices long before one found its way into the Second Chest. But as the company grew, and expanded into other medical markets, it found that its strategic ambitions sometimes outpaced its balance-sheet management.

Complete your profile to continue reading and get FREE access to Treasury & Risk, part of your ALM digital membership.

  • Critical Treasury & Risk information including in-depth analysis of treasury and finance best practices, case studies with corporate innovators, informative newsletters, educational webcasts and videos, and resources from industry leaders.
  • Exclusive discounts on ALM and Treasury & Risk events.
  • Access to other award-winning ALM websites including PropertyCasualty360.com and Law.com.

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Susan Kelly

Susan Kelly is a business journalist who has written for Treasury & Risk, FierceCFO, Global Finance, Financial Week, Bridge News and The Bond Buyer.